Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 06/08

20080154022 - Transport of basic fibroblast growth factor across the blood brain barrier: Compositions and methods for increasing the receptor mediated transport of basic fibroblast growth factor (bFGF) across the blood brain barrier (BBB). The bFGF is conjugated to a BBB targeting agent using either avidin-biotin technology or genetic engineering. The bFGF conjugate was found to cross the BBB at substantially increased rates... Agent: Quine Intellectual Property Law Group, P.c.

20080154023 - Methods and compositions with reduced opalescence: Methods for reducing the opalescent appearance of a protein preparation by modifying the ionic strength of the preparation, as well as compositions, e.g., pharmaceutical compositions, of concentrated protein with decreased opalescence are disclosed. Purification methods which monitor and/or reduce the salt concentrations at selected steps are also disclosed.... Agent: Choate, Hall & Stewart LLP/wyeth

20080154024 - Method of selective arrangement of ferritin: A method for selectively arranging ferritin in a specified inorganic material part formed on a substrate is provided. The method for arranging ferritin of the present invention is characterized in that ferritin is selectively arranged on a part including titanium or silicon nitride (SiN) in an efficient manner by adding... Agent: Mcdermott Will & Emery LLP

20080154025 - Fc variants with increased affinity for fcyriic: The present invention relates to Fc variants having increased affinity for FcγRIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.... Agent: Morgan, Lewis & Bockius, LLP

20080146778 - Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs comprising same: where X is alky1-6 or is not present, Y is N or O or is not present, and R3 is alkyl1-6; PAG is a linear or branched polyalkylene glycol moiety; R2 is an alkyl1-22 capping moiety if X is present or alkyl2-22 if X is not present; and q is... Agent: Moore & Van Allen Pllc

20080146779 - Novel melanocortin receptor templates, peptides, and use thereof: The present invention relates to novel chimeric peptides and templates containing a combination of antagonist and agonist endogenous ligand residues. In particular, the present invention relates to novel chimeric peptides and templates thereof based upon melanocortin agonist peptides and agouti related protein (AGRP). The present invention provides multifunctional chimeric peptides... Agent: Margaret Efron Saliwanchik, Lloyd & Saliwanchik

20080146780 - Mn gene and protein: Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked... Agent: Leona L. Lauder

20080146781 - Modified human four helical bundle polypeptides and their uses: Modified human four helical bundle (4HB) polypeptides and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080146782 - Glycerol linked pegylated sugars and glycopeptides: The present invention provides conjugates between peptides and PEG moieties through glycerol linkers.... Agent: Morgan, Lewis & Bockius LLP (sf)

20080146783 - Method for the purification of albumin conjugates: The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration;... Agent: Jones Day

20080146784 - Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.... Agent: Immunomedics, Inc.

20080146785 - Antibody against tumor specific antigen as target: The present invention relates to a method of detecting cancer by use of an oncogene, a method of screening for an active compound useful to treat and/or prevent cancer, and a pharmaceutical composition for treatment and/or prevention of cancer. More specifically, the present invention provides a method of detecting cancer... Agent: Dorsey & Whitney LLP Intellectual Property Department

20080146786 - Fret protease assays for botulinum serotype a/e toxins: The present invention provides clostridial toxin substrates useful in assaying for the protease activity of any clostridial toxin, including botulinum toxins of all serotypes as well as tetanus toxins. A clostridial toxin substrate of the invention contains a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum... Agent: Allergan, Inc.

20080139783 - Compositions and methods for detecting treponema pallidum: Methods for the specific and highly sensitive detection of Treponema pallidum infection comprising the use of specific antigenic proteins and peptides unique to Treponema pallidum are provided. In particular, detection assays based on recognition of acidic repeat protein are provided. The methods of the present invention are useful for detection... Agent: Klarquist Sparkman, LLP

20080139784 - Preparation of insulin conjugates: The present invention discloses a process for making an insulin-oligomer conjugate as a one-pot reaction by conjugation of insulin-ester with an activated oligomer wherein simultaneous deblocking and conjugation is carried out.... Agent: Banner & Witcoff, Ltd.

20080139785 - Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis: The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage including a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) covalently bound to X.... Agent: Clark & Elbing LLP

20080139786 - Dye compounds as photoactive agents: e

20080139787 - Fluorine-labeled compounds: Methods for introducing fluorine atom onto a polypeptide are provided. Also provided are linkers, bioconjugates, and bifunctional compound agents made using the methods, linkers, and bioconjugates. The methods comprise: (i) providing a linker comprising a thiol-reactive terminus and an aldehyde-reactive terminus; (ii) reacting the thiol-reactive terminus of the linker with... Agent: General Electric Company Global Research

20080139788 - Acridone derivatives as labels for fluorescence detection of target materials: in which Z1 and Z2 represent the atoms necessary to complete one ring, two fused ring, or three fused ring aromatic or heteroaromatic systems, each ring having five or six atoms selected from carbon atoms and optionally no more than two atoms selected from oxygen, nitrogen and sulphur; R2, R3,... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20080139789 - Isolated broadly reactive opsonic immunoglobulin for treating a pathogenic coagulase-negative staphylococcus infection: The invention describes the identification, making, and isolation of immunoglobulin and antigen useful for preventing, diagnosing, and treating staphylococcal infections. The invention further describes an in vivo animal model useful for testing the efficacy of pharmaceutical compositions, including pharmaceutical compositions of immunoglobulin and isolated antigen.... Agent: Lahive & Cockfield, LLP

20080139790 - Chimeric antibodies: The present invention provides a chimeric antibody or an antigen-binding portion thereof. The antigen-binding portion comprises at least two complementarity determining regions (CDR) and at least three framework regions, wherein at least one CDR is a New World primate CDR.... Agent: Morrison & Foerster LLP

20080139791 - Pharmaceutically acceptable fn3 polypeptides for human treatments: Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.... Agent: Ropes & Gray LLP

20080139792 - High protein concentration formulations containing mannitol: The present invention provides a method for inhibiting mannitol-induced aggregation of a protein in a liquid formulation by increasing the protein concentration to an amount greater than 50 mg/ml. The present invention also provides methods for storing and preparing a liquid formulation containing mannitol and a protein concentration greater than... Agent: Choate, Hall & Stewart LLP/wyeth

20080139793 - Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides: Disclosed herein are accelerants for the formation of oxime-containing compounds from the reaction of a carbonyl-containing compound and a hydroxylamine-containing compound. The oxime-containing compound, the carbonyl-containing compound and the hydroxylamine-containing compound can each be a non-natural amino acid or a non-natural amino acid polypeptide. Also disclosed is the use of... Agent: Wilson Sonsini Goodrich & Rosati

20080139794 - Accelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides: Disclosed herein are accelerants for the formation of oxime-containing compounds from the reaction of a carbonyl-containing compound and a hydroxylamine-containing compound. The oxime-containing compound, the carbonyl-containing compound and the hydroxylamine-containing compound can each be a non-natural amino acid or a non-natural amino acid polypeptide. Also disclosed is the use of... Agent: Wilson Sonsini Goodrich & Rosati

20080132678 - Boronic ester and acid compounds, synthesis and uses: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.... Agent: Millennium Pharmaceuticals, Inc.

20080132679 - Peptide capable of binding to insulin-binding protein and adsorbent: s

20080132680 - Cytokine protein family: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral... Agent: Zymogenetics, Inc. Intellectual Property Department

20080132681 - Human interferon molecules and their uses: Modified human interferon polypeptides and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080132682 - Method for manufacturing gelatin with reduced endotoxin content and low endotoxin gelatin: A method of manufacturing gelatin with reduced endotoxin content. The method comprises processing a starting material gelatin-containing solution containing gelatin and an endotoxin with an ultrafiltration film having a molecular weight cut-off falling within a range of from 20,000 to 300,000 and having a molecular weight cut-off capable of passing... Agent: Ditthavong Mori & Steiner, P.c.

20080132684 - Assay method for group transfer reactions: The present invention relates to methods for detecting, quantifying and high throughput screening of donor-products and the catalytic activities generating the donor-products in group-transfer reactions. The invention further provides immunoassays, antibodies and kits that may be used to practice the methods of the invention.... Agent: Quarles & Brady LLP

20080132683 - Isolation of immunoglobulins: The present invention relates to a novel method for the isolation or purification of immunoglobulins (a special class of proteins) from a solution containing immunoglobulins, e.g. hybridoma cell culture supernatants, animal plasma or sera, or colostrum. The method includes the use of a minimum of salts, such as lyotropic salts,... Agent: Foley And Lardner LLP Suite 500

20080132685 - Methods and compositions for detecting amyotrophic lateral sclerosis: The invention provides binding proteins that bind to misfolded or monomeric SOD1, and not to native homodimeric SOD1. The invention also includes methods of diagnosing, detecting or monitoring amyotrophic lateral sclerosis in a subject. In addition, the invention provides methods of identifying substances for the treatment or prevention of amyotrophic... Agent: Bereskin And Parr

20080132686 - Antibodies against insulin-like growth factor i receptor and uses thereof: Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Such antibodies are implicated in antitumor therapy.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080132687 - Pharmaceutical preparation for the treatment of friedreich's ataxia: Use of human erythropoietin or a derivative thereof having the biological activity of human erythropoietin of increasing the expression of frataxin for the production of a pharmaceutical preparation for the treatment of Friedreich's ataxia or for the treatment or prevention of a disease associated therewith.... Agent: Workman Nydegger

20080132688 - Methods for removing viral contaminants during protein purification: The present invention relates, in general, to methods for removing viral contaminants from therapeutic protein solutions to improve safety of therapeutic proteins administered to patients. Particularly contemplated is the removal of small non-enveloped viruses, such as parvovirus, from therapeutic protein solutions.... Agent: Marshall, Gerstein & Borun LLP